Want to see JP:6029 full AI Analyst Report?
Top Page
Artra Group Corporation
(6029)
Select Model
Select Model
Rating:62Neutral
Price Target:
¥208.00
▲(22.35% Upside)
Action:Reiterated
Date:08/04/26
The score is primarily driven by improving profitability and deleveraging, offset by multi-year revenue contraction and historically volatile earnings/cash flow. Technicals are modestly constructive with a supportive longer-term trend but neutral near-term momentum, while valuation appears reasonable with a P/E near 12.
Positive Factors
Margin Recovery
Recovered net and EBITDA margins in 2025 indicate the business has re-established pricing power or cost control after prior losses. Sustained mid-single-digit margins improve cash flow convertibility and provide a buffer for reinvestment or debt paydown, supporting financial resilience over the next several quarters.
Negative Factors
Multi-year Revenue Decline
Sustained top-line contraction erodes scale economies and limits the durability of margin recovery. With revenues trending down, growth will likely rely on market share gains or new services; absent that, fixed costs become harder to cover and long-term organic growth prospects remain constrained.
Read all positive and negative factors
Positive Factors
Negative Factors
Margin Recovery
Recovered net and EBITDA margins in 2025 indicate the business has re-established pricing power or cost control after prior losses. Sustained mid-single-digit margins improve cash flow convertibility and provide a buffer for reinvestment or debt paydown, supporting financial resilience over the next several quarters.
Read all positive factors
Artra Group Corporation (6029) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥1.95B
Dividend YieldN/A
Average Volume (3M)28.86K
Price to Earnings (P/E)19.7
Beta (1Y)0.70
Revenue Growth-9.90%
EPS Growth-32.08%
CountryJP
Employees131
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)16.00
Shares Outstanding10,487,000
10 Day Avg. Volume21,570
30 Day Avg. Volume28,856
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.03
Price to Sales (P/S)0.44
P/FCF Ratio7.08
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Artra Group Corporation Business Overview & Revenue Model
Company Description
Artra Group Corporation delivers diverse support services to acupuncture and osteopathic clinics across Japan. Its offerings encompass billing solutions and HONEY-STYLE, a specialized platform facilitating word-of-mouth marketing and reservation m...
How the Company Makes Money
null...
Artra Group Corporation Financial Statement Overview
Summary
Income Statement
58
Neutral
Balance Sheet
64
Positive
Cash Flow
61
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.92B | 3.93B | 4.23B | 4.50B | 4.67B | 3.16B |
| Gross Profit | 1.36B | 1.35B | 1.33B | 1.46B | 1.57B | 876.25M |
| EBITDA | 371.06M | 360.55M | 146.84M | 228.12M | 190.55M | -163.55M |
| Net Income | 164.27M | 258.29M | -36.74M | 53.00M | 2.10M | -351.12M |
Balance Sheet | ||||||
| Total Assets | 3.38B | 4.13B | 4.11B | 4.57B | 4.65B | 5.60B |
| Cash, Cash Equivalents and Short-Term Investments | 1.27B | 1.13B | 1.05B | 1.14B | 1.23B | 1.84B |
| Total Debt | 791.72M | 1.05B | 1.29B | 1.54B | 1.91B | 2.44B |
| Total Liabilities | 1.79B | 2.43B | 2.68B | 3.13B | 3.35B | 4.16B |
| Stockholders Equity | 1.59B | 1.70B | 1.44B | 1.45B | 1.31B | 1.44B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 246.64M | 122.36M | 142.00M | -288.93M | -264.76M |
| Operating Cash Flow | 0.00 | 287.21M | 200.85M | 217.00M | -132.55M | -208.56M |
| Investing Cash Flow | 0.00 | 24.68M | -31.16M | -11.00M | -154.17M | -563.84M |
| Financing Cash Flow | 0.00 | -233.24M | -259.74M | -300.00M | -314.62M | 895.50M |
Artra Group Corporation Technical Analysis
Negative
170.00
Price Trends
191.90
Negative
188.81
Negative
175.82
Positive
Market Momentum
-2.23
Positive
43.32
Neutral
52.38
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:6029, the sentiment is Negative. The current price of 170 is below the 20-day moving average (MA) of 190.70, below the 50-day MA of 191.90, and below the 200-day MA of 175.82, indicating a neutral trend. The MACD of -2.23 indicates Positive momentum. The RSI at 43.32 is Neutral, neither overbought nor oversold. The STOCH value of 52.38 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:6029.
Artra Group Corporation Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | ¥3.13B | 6.98 | ― | 2.82% | 5.48% | 13.46% | |
67 Neutral | ¥1.81B | 15.57 | ― | ― | 28.60% | -22.35% | |
62 Neutral | ¥1.95B | 19.75 | ― | ― | -9.90% | -32.08% | |
56 Neutral | ¥2.51B | 29.72 | ― | 2.56% | -5.72% | -73.78% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | ¥1.34B | 9.28 | ― | ― | 14.48% | 71.76% | |
49 Neutral | ¥5.49B | 52.63 | ― | 4.07% | 4.85% | -85.27% |
* Healthcare Sector Average
JP:6029
Artra Group Corporation
186.00
-30.00
-13.89%
JP:2373
Care Twentyone Corporation
410.00
5.72
1.41%
JP:2425
Care Service Co., Ltd.
661.00
-121.52
-15.53%
JP:7362
Terminalcare Support Institute, Inc.
884.00
58.07
7.03%
JP:9214
Recovery International Co.,Ltd.
1,280.00
-339.00
-20.94%
JP:9220
FB CARE SERVICE CO.,LTD.
1,267.00
128.71
11.31%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.